Fig. 5. Anti-hET_A AG8 suppressed the growth of colorectal cancer cells.

a, b Inhibition of the proliferation of colorectal cancer cells (HT-29 (a) and HCT-116 (b)) treated with AG8 IgG. Cancer cells were seeded in 96-well plates in the presence of AG8 and incubated for 72 h. c Western blot analysis of phosphorylated AKT and ERK levels in HCT-116 colorectal cancer cells treated with ET-1 (10 nM) for 10 min with or without pretreatment with AG8 (100 μg) for 4 h. β-Actin was used as the loading control. d The mRNA expression of INHBA in HCT-116 cells treated with ET-1 (10 nM) for 24 h with or without pretreatment with AG8 (100 μg) for 4 h. e HT-29 cells were subcutaneously injected into nude mice. Tumor-bearing mice were randomized, and AG8 (1.125 mg/kg) was intratumorally injected into each mouse at intervals of 2 days. f Photos of dissected tumor masses on Day 27. The error bars show the mean ± standard deviation values; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 vs. control.